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Background: Expression of recombinant antibodies and their 
derivatives fused with other functional molecules such as al-
kaline phosphatase in Escherichia coli is important in the de-
velopment of molecular diagnostic reagents for biomedical 
research. Methods: We investigated the possibility of apply-
ing a well-known Fos-Jun zipper to dimerize VH and VL frag-
ments originated from the Fab clone (SP 112) that recog-
nizes pyruvate dehydrogenase complex-E2 (PDC-E2), and 
demonstrated that the functional zipFv-112 and its alkaline 
phosphatase fusion molecules (zipFv-AP) can be produced in 
the cytoplasm of Origami(DE3) trxB gor mutant E. coli 
strain.  Results: The zipFv-AP fusion molecules exhibited 
higher antigen-binding signals than the zipFv up to a 10-fold 
under the same experimental conditions. However, con-
formation of the zipFv-AP seemed to be influenced by the lo-
cation of an AP domain at the C-terminus of VH or VL domain 
[zipFv-112(H-AP) or zipFv-112(L-AP)], and inclusion of an 
AraC DNA binding domain at the C-terminus of VH of the 
zipFv-112(L-AP), termed zipFv-112(H-AD/L-AP), was also 
beneficial. Cytoplasmic co-expression of disulfide-binding 
isomerase C (DsbC) helped proper folding of the zipFv- 
112(H-AD/L-AP) but not significantly. Conclusion: We be-
lieve that our zipFv constructs may serve as an excellent an-
tibody format bi-functional antibody fragments that can be 
produced stably in the cytoplasm of E. coli.
[Immune Network 2010;10(2):35-45]
INTRODUCTION
Recombinant  antibodies  composed  of  antigen-binding  frag-
ments of whole antibodies such as Fv, scFv or Fab have been 
acknowledged  to  have  many  applications  in  biological  re-
search. They also offer several advantages including the pro-
duction of functional forms in bacteria and easy genetic ma-
nipulation  to  confer  desired  features  to  the  antigen-binding 
fragments (1,2). The smallest functional unit of antibodies re-
quired for proper antigen binding is an Fv fragment, a hetero-
dimer of the heavy chain variable domain (VH) and the light 
chain variable domain (VL). Unlike whole IgG or Fab mole-
cules, however, the dissociation constant between the VH and 
VL domains of an Fv fragment ranges only from 10
−5∼10
−8 
M,  which  is  not  sufficient  to  keep  the  domains  associated 
with each other since there are no interchain disulfide inter-
actions  (3-5).
  A s  a n  a l t e r n a t i v e ,  V H a n d  V L  domains  are  connected  via 
a short peptide linker so that stable Fv fragments can be pro-
duced as a single polypeptide in Eschericha coli. Such sin-
gle-chain  variable  fragments  (scFv)  are  generally  known  to 
retain antigen-binding specificity and affinity of the parent an-
tibody (6-9). The scFv format of an antibody molecule has 
a distinctive advantage over its Fab counterpart in that high 
yield can be obtained in E. coli because of a single polypep-
tide structure in nature. In some cases, however, scFv frag-
m e nt s a re  u ns ta bl e a nd  h av e  a m u ch  lo w er  af fin it y  ag ai ns t Cytoplasmic Expression of zipFv Fragments in E. coli
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the antigens than that of Fab or whole Ig counterpart, espe-
cially when they are fused to toxins for constructing recombi-
nant  immunotoxins,  probably  due  to  the  interference  of  a 
peptide linker with antigen binding or in sufficient stabiliza-
tion of the Fv molecules (10,11). To circumvent this draw-
back,  it  had  been  attempted  to  uitlize  a  disulfide-stabilized 
Fv (dsFv) fragment that can be generated by introducing in-
terchain disulfide bonds artificially at the framework regions 
of VH and VL domains (12,13). A dsFv fragment is found to 
be considerably more stable and shows better antigen-binding 
capacity than the corresponding scFv counterpart, suggesting 
that dsFv format is more useful than scFv as therapeutic and 
diagnostic  reagents  (14,15).  Unfortunately,  generation  of  a 
dsFv is not trivial because appropriate amino residues in con-
served framework regions have to be identified for the disul-
fide bridge by molecular modeling technology, followed by 
cumbersome  point-directed  mutagenesis.
    Another  problem  in  producing  functional  antibody  frag-
ments,  even  scFv,  in  E.  coli i s  t h a t  a  r e d u c e d  s t a t e  o f  t h e  
E. coli cytoplasm acts strongly against the formation of disul-
fide  bonds  in  proteins  (16).  Therefore,  antibody  fragments 
must be secreted to the periplasmic space, but it frequently 
leads to a low yield of soluble antibody fragments primarily 
due to the aggregation and degradation of the fragments in 
the periplasm, inefficient translocation through the cytoplas-
mic membrane, and lysis of host cells in many cases (17-19). 
Expression of antibody fragments in the cytoplasm of E. coli 
may alleviate cellular toxicity if the mutant trxB E. coli strain 
that has much oxidizing cytoplasmic environment were uti-
lized so that the formation of disulfide bonds of polypeptides 
in the  cytoplasm is allowed  (20).  For examples, high  yield 
of functional scFv fragments from the anti-progesterone anti-
body, DB3, has been obtained by cytoplasmic expression of 
the antibody fragments using E. coli ADA494 strain (trxB mu-
tant) (21,22), and soluble Fab antibody fragments have also 
been successfully produced in the cytoplasm of E. coli trxB 
gor  mutant  (23,24).
  In this study, we accessed the possibility of producing a 
novel functional Fv fragment, named zipFv, by linking VH and 
VL fragments via Fos/Jun leucine zipper and its fusion poly-
p e p t i d e s  w i t h  a l k a l i n e  p h o s p h a t a s e  ( A P ) ,  n a m e d  z i p F v - A P ,  
and demonstrated that the functional zipFv and the zipFv-AP 
antibody fragments can be expressed in the cytoplasm of E. 
coli trxB gor mutant using the VH and the VL domains from 
SP112, the human Fab clone specific for pyruvate dehydro-
genase  complex-E2  (PDC-E2 ) ,  a s  a  m o d e l  s y s t e m .
MATERIALS AND METHODS
Bacterial strains and oligonucleotides
Escherichia coli strain ElectroTen Blue (∆(mcrA)183 ∆(mcrCB- 
hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac 
Kan
R [F' proAB lacIqZ∆M15 Tn10 (Tet
R)]) (Stratagene, USA) 
was used as the bacterial host for the preparation of recombi-
nant  vectors  and  DNA  cloning,  and  Origami(DE3)  (∆(ara- 
leu)7697  ∆lacX74  ∆p h o A  P v u I I  p h o R  a r a D 139  aphC  galE 
galK  rpsL F '[lac
＋ lacI
q p ro ] (DE3) gor522::Tn10  trxB  (Kan
R, 
Str
R, Tet
R)) (Novagen, USA) for the expression of recombinant 
antibody  fragments.  All  oligonucleotides  used  in  this  study 
were  synthesized  from  Bioneer  Co.  (South  Korea).
DNA cloning procedure
All DNA cloning experiments were carried out according to 
the  standard  procedures  (25),  and  Ex-Taq  polymerase  and 
Pfu DNA polymerase (Takara, Japan) were successfully used 
for  the  polymerase  chain  reactions  (PCR).  The  pCzFv, 
p C z F v H A P  a n d  p C z F v L A P  v e c t o r s  w e r e  c o n s t r u c t e d  p r e -
viously  as  shown  in  Fig.  1  (IG  Therapy,  South  Korea.  un-
published). The VH and the VLκ chain genes were PCR ampli-
fied from SP112 Fab clone (26) at the condition of 35 cycles 
of 94
oC 1 min, 55
oC 1 min, 72
oC 1 min, followed by 72
oC 
soaking for 10 min using human Ig-specific VH and JH, or VLκ 
and Jκ primers synthesized according to the previous report 
with  slight  modification  (VH  sense:  5'-GGGGGCCCAGCCG-
GCCATGGCCGAGGTGCAGCTGGTGGAGTCTGG-3',  JH a n t i -
sense:  5'-GGGGGCCACATTGGCCGATGAGGAGACGGTGAC-
CAKGGTBCCTTGGCCCCA-3', Vκ sense: VLκ forward: 5'-GGG-
GTCGACATGGAAATTGAGTTGACGCAGTCTCC-3', Jκ antise-
nse: 5'-GGGCCGCGGATACGTTTGATHTCCASYTTGGTCCC-3'; 
where Sfi I, Sal I and Sac II recognition sites were underlined, 
and degeneracy is denoted as follows: H=A, C or T; S=G or 
C ;  Y = C  o r  T ;  K = G  o r  T ;  B = G ,  T  o r  C )  ( 2 7 ) .
  T h e  V Lκ gene fragment of SP112 was recovered from 1.2% 
agarose gel, treated with Sal I and Sac II (Takara), and cloned 
into pCzFv, pCzFvHAP and pCzFvLAP at a 2：1 molar ratio 
using T4 DNA ligase (Takara) at 16
oC overnight. The resulting 
DNA  ligated  reactions  were  electroporated  into  ElectroTen 
Blue competent cells using Gene Pulser (Biorad, USA) at 2.5 
kV, 25μF and 400Ω, and the transformed cells were recov-
ered by growing them in SOC medium for 1 h at 37
oC. Then, 
the cell suspensions were spread onto 2× YT plates contain-
ing 50μg/ml ampicillin (2× YT/amp). E. coli colonies carry-
ing pCzFv, pCzFvHAP or pCzFvLAP vectors with correct VLκ Cytoplasmic Expression of zipFv Fragments in E. coli
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Figure 1. Schematic diagram depict-
ing the cytoplasmic zipFv expression
vectors used in this study.
insert were identified by cutting the miniprep plasmid with 
Sal I  a n d  Sac  II,  followed  by  1.2%  agarose  gel  electro-
phoresis. Thereafter, the VH gene obtained from SP112 was 
treated with Sfi I (Takara), and subsequently cloned into the 
pCzFv,  pCzFvHAP,  and  pCzFvLAP  vectors  containing  VLκ 
inserts. The resulting pCzFv, pCzFvHAP and pCzFvLAP vec-
tors  having  both  VH  and  VLκ  genes  of  SP112  were  named 
as pCzFv-112, pCzFvHAP-112 or pCzFvLAP-112, respectively, 
and  electroporated  into  Origami(DE3)  cells.
    The gene encoding a DNA binding domain of AraC (amino 
acid  residues  168∼291)  (AraCDNA)  (28,29)  was  obtained  by 
PCR  amplification  from  the  pBAD/gIII  vector  (Invitrogen, 
U S A )  u s i n g  P C R  p r i m e r s  ( s e n s e :  5 ' - G G G A C T A G T AACGAG-
TCGCTCCATCCACCG-3';  antisense:  5'-GGGGTCGACACTAG-
TTTATGACAACTTGACGGCTAC ATCA-3', where Spe I recog-
nition site was underlined). The resulting 408 bp PCR prod-
ucts were digested with Spe I restriction enzyme, and cloned 
into the pCzFvLAP-112 that had been treated with Nhe I. The 
ligation reaction was electroporated into ElectroTen Blue cells 
and  finally  into  Origami(DE3)  as above. The resulting con-
s t r u c t  w a s  n a m e d  p C z F v H A D L A P - 1 1 2 .
    For the cytopalsmic co-expression of DsbC, the full-length 
E. coli DsbC gene without signal peptide sequence was ob-
tained from the genomic DNA of BL21(DE3) cells by PCR us-
ing  following  PCR  primers  (sense:  5'-GGGCATATGGATGA-
CGCGGCAATTCAACAA-3',  antisense:  5'-GGGGGTACCTTAT-
TTACCGCTGGTCATTTTTTG-3',  Nde I and Kpn I restriction 
sites were underlined). The resulting PCR products were re-
covered from 1% agarose gel using Wizard DNA purification 
kit (Promega, USA). Then the DNA fragments were restricted 
with Nde I/Kpn I, and cloned into pCDFDuet (Novagen), re-
sulting in the construction of pCDF-DsbC. Origami(DE3) cells 
were  transformed  with  the  construct,  and  selected  with  LB 
medium supplemented with 50μg/ml of spectinomycin (Sig-
ma  Co.).
Preparation of antigens 
Recombinant inner lipoyl domain of human PDC-E2 (residues 
91∼227)  fused  to  glutathione  S-transferase  (GST)  was  pre-
pared by growing E. coli having pGEX vector with PDC-E2 
inner lipoyl domain cDNA in 200 ml of LB containing 50μg/ml 
ampicillin (LB/amp) supplemented with 1 mM isopropyl-β- 
D-1-thiogalactopyranoside  (IPTG)  until  OD600=0.5  at  37
oC 
(30). The cell culture was centrifuged at 3,000×g for 10 min, 
and  the  resulting  cell  pellet  was  resuspended  in  5  ml  of 
ice-cold phosphate-buffered saline (PBS) supplemented with 
1% Triton X-100 (Sigma Co.). The cell suspension was soni-
cated 5 times for 5 sec each with 2 min intervals on ice in 
the  presence  of  100μg/ml  phenylmethylsulfonyl  fluoride 
(PMSF) (Sigma Co.), and microfuged for 5 min at 4
oC to re-Cytoplasmic Expression of zipFv Fragments in E. coli
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move cell debris. For the purification of the protein, gluta-
thione-agarose  bead  (Sigma  Co.)  in  2  ml  PBS  were  mixed 
with the supernatant at 4
oC overnight, washed with ice-cold 
PBS  4  times,  and  recombinant  proteins  were  eluted  with  5 
mM reduced glutathione (Sigma Co.) in 50 mM Tris-Cl (pH 
8.0).  Negative  control  antigens  were  prepared  as  follow. 
Maltose binding protein (MBP) was prepared by growing E. 
coli  harboring  pMAL-c2  (New  England  Biolab,  USA)  using 
amylose-binding  resin  according  to  the  manufacturer’s  pro-
tocol. Human recombinant IL-15 proteins were produced by 
using pET expression system and purified with Ni-NTA resin 
(IG Therapy Co., unpublished). Bovine serum albumin (BSA) 
was  purchased  from  Sigma  Co.
Production of the zipFv and the zipFv-AP fragments
Origami(DE3) cells carrying pCzFv-112, pCzFvHAP-112, pCz-
FvLAP-112 or pCzFvHADLAP-112 were grown on 5 ml of 2× 
YT/amp until OD600=approximately 0.5. Then IPTG was add-
ed into the culture at 0.1 mM final concentration, and pro-
duction of the zipFv molecules was induced at 27
oC for 16 
h. The cells were harvested by centrifugation (4,000 rpm for 
10 min) and resuspended in 2 ml of cold PBS containing 100
μg/ml of PMSF. The cell suspension was sonicated 5 times 
on ice, and microfuged for 5 min at 4
oC to obtain cytoplasmic 
extract. The resulting cytoplasmic extracts were used in the 
enzyme-linked immunosorbent assay (ELISA). For the co-ex-
pression of DsbC and the zipFv-AP fusion molecules, electro-
competent cells were prepared with Origami(DE3) cells hous-
ing pCDF-DsbC, and pCzFvHADLAP-112 was introduced into 
the cells by electroporation as described previously. The cells 
having  both  pCDF-DsbC  and  pCzFvHADLAP-112  were  se-
lected  by  growing  them  in  2×  YT/amp  medium  supple-
mented  with  50μg/ml  of  spectinomycin.
ELISA
Maxisorp 96-well plates (Nunc, Denmark) were coated with 
50μl of 10μg/ml PDC-E2, recombinant human IL-15, MBP, 
or BSA in coating buffer (0.1 M NaHCO3, pH 9.6) at 4
oC over-
night  and  blocked  with  3%  powdered  milk  in  PBS  (MPBS) 
for 2 h at room temperature. Then, serial dilutions of the cy-
toplasmic extracts (50μl) were added into each of the micro-
wells, and incubated for 2 h at 27
oC. The plates were washed 
four times with PBS containing 0.05% Tween 20 (PBST), and 
mouse anti-myc tag monoclonal antibody (mAb) (IG Therapy, 
Co.)  followed  by  goat  anti-mouse  IgG-horse  radish  perox-
idase  (HRPO)  conjugated  (Sigma  Co.)  was  added  and  in-
cubated  for  1  h  at  27
oC,  respectively.  The  signal  was  vi-
sualized  by  adding  50μl  of  3.3',5.5'-tetramethyl  benzidine 
(TMB) substrate (Sigma Co.), and the enzymatic reaction was 
stopped by adding an equal volume  of 1  N HCl into each 
well.  Finally,  absorbance  at  450  nm  was  measured  using 
ELISA  reader  (Biorad).  In  order  to  determine  the  alkaline 
phosphatase activity (AP) of the zipFv-AP fusions bound to 
antigens, 50μl of p-nitrophenyl phosphate (pNPP) substrate 
(Sigma Co.) were directly added into each well instead of us-
ing anti-myc tag mAb. The enzymatic reaction was stopped 
by adding 3 N NaOH into each well, and absorbance at 405 
nm  was  measured  using  ELISA  reader.
Western blot
Origami(DE3)  cells  carrying  pCzFv-112,  pCzFvHAP-112  or 
pCzFvLAP-112 were grown in 2 ml of 2× YT/amp medium 
at 37
oC until OD600 reached approximately 0.5, and the ex-
pression of the zipFv and its AP fusion proteins was induced 
as above. The cells were harvested by microfugation and re-
suspended  with  SDS  sample  buffer  with  or  without  β-2- 
mercaptoethanol,  and  total  cellular  proteins  were  separated 
with 12% SDS-PAGE (25). The proteins were transferred to 
nitrocellulose  membrane  (Amersham  Pharmacia,  Sweden), 
and the membrane was blocked with MPBS. After washing 
the membrane three times with PBST, anti-myc tag mAb fol-
lowed by incubation with goat anti-mouse IgG-alkaline phos-
phatase (AP) conjugated (Sigma Co.), or nitro blue tetrazo-
lium  chloride  (NBT)/5-bromo-4-chloro-3-indolyl  phosphate 
(BCIP) substrate (Sigma Co.) directly was used to detect the 
presence of the zipFv or its AP activity in total E. coli lysate. 
The  bands  on  the  blot  were  analyzed  with  densitometer 
(Biorad).
RESULTS
Construction of zipFv expression vectors
It is well accepted that bacterially expressed  antibody  frag-
ments (Fv, scFv or Fab) provide a simple and cost-effective 
alternative  to  the  traditional  production  of  diagnostic  mAbs 
by animal cell tissue culture, and numerous recombinant anti-
body  fragments  have  been  successfully  produced  through 
periplasmic  expression  using  E.  coli.  Although  scFv  format 
is advantageous in prokaryotic expression because of its sin-
gle  polypeptide  structure,  disulfide-stabilized  Fv  (dsFv)  had 
also  been  recognized  to be  more  useful  than  scFv  as  ther-
apeutic and diagnostic agent through its superior stabilization Cytoplasmic Expression of zipFv Fragments in E. coli
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(14). SP112, a human Fab binds to PDC-E2, was chosen in 
t h i s  s t u d y  b e c a u s e  i t  i s  a v a i l a b l e  i n  o u r  l a b o r a t o r y  a t  h a n d 
and a scFv version of SP112 does not show any significant 
antigen-binding  reactivity  to  PDC-E2  (data  not  shown).
    To  evaluate  whether  heterodimerization  of  VH a n d  V L o f  
SP112 via Fos (40 amino acid residues in size)/Jun (40 amino 
acid  residues  in  size)  leucine  zipper  could  retain  the  anti-
gen-binding  reactivity,  a  new  Fv  expression  vector,  pCzFv, 
was  constructed  using  the  pET22b  expression  vector  as  a 
backbone (Fig. 1). The Fos：Jun leucine zippers were used 
to link VH and V L fragments since they preferentially form het-
erodimers (Fos：Jun) at least 1,000 times over homodimers 
(Fos：Fos or Jun：Jun) due to greater thermodynamic stabil-
ity (31), and the same amphiphilic helix leucine zipper had 
already been successfully used in the generation of dimeric 
and  bispecific  scFv  fragments  (2).
    The  bicistronic  expression  of  VH-Fos-myc  and  VL-Jun-S1 
gene fragments driven by a single p7 promoter ensures the 
equal transcription of the fragments, and partial mouse IgG3 
hinge  fragments  (10  amino  acid  residues  in  size)  are  in-
t r o d u c e d  b e t w e e n  t h e  V H  and  Fos  domains  as  well  as  be-
tween the VL and Jun domains to confer structural flexibility. 
Two cysteine residues are also added at the flanking region 
of each Fos and Jun segment, respectively, so that two inter-
chain disulfide bonds could be formed in the zipper region 
to  reinforce  the  binding  of  Fos/Jun  dimer  (2).  In  addition, 
myc tag and S1 tag are placed at the end of Fos or Jun, re-
spectively,  to  facilitate  the  detection  of  each  antibody  frag-
ments.
    As similar to a scFv-AP fusion produced in the periplasm 
of bacteria (32), fusion of AP to the zipFv might be advanta-
geous  in that  binding of  the  antibody  fragments  to  antigen 
can be analyzed in an ELISA or Western blot without use of 
additional enzyme-conjugated antibodies. Thereby, the pCzFv 
vector was further modified to pCzFvHAP or pCzFvLAP vector 
by linking leaderless phoA gene (1,470 bp in length) encod-
ing alkaline phosphatase (AP) (46.5 kDa in size) at the 3' end 
of either the VH-Fos-myc or the VL-Jun-S1 gene fragment, re-
spectively,  to  produce  the  zipFv-AP  fusion  proteins  [zipFv- 
112(H-AP)  or  zipFv-112(L-AP)].  Finally,  the  VH  and  the  VL 
genes of SP112 were cloned into the pCzFv, pCzFvHAP and 
pCzFvLAP vectors, and the resulting vector constructs, named 
as  pCzFv-112,  pCzFvHAP-112  and  pCzFvLAP-112,  respec-
tively, were electroporated into Origami(DE3) trxB gor mutant 
E.  coli c e l l s .
Expression and characterization of the zipFv and the 
zipFv-AP fusion proteins
The  Origami(DE3)  trxB  gor  cells  carrying  pCzFv-112,  pCz-
FvHAP-112 or pCzFvLAP-112 were grown in 2× YT/amp me-
dium,  and  the  recombinant  antibody  fragments  were  ex-
pressed by adding 0.1 mM IPTG at 27
oC for 16 h. The zipFv 
and  the  zipFv-AP  fusion  proteins  produced  by  each  of  the 
host  cells  were  named  as  zipFv-112,  zipFv-112(H-AP)  or 
zipFv-112(L-AP),  respectively,  The  optimal  induction  con-
dition had been pre-determined using various concentrations 
of  IPTG  (0∼1  mM),  temperature  (27
oC  or  37
oC)  and  in-
duction time (2∼16 h). Growing cells at 27
oC for 16 h pro-
duced at least 1∼3 times more functional zipFv and zipFv-AP 
fusion fragments than at 37
oC for 4 h, and 0.1 mM final con-
centration of IPTG gave the highest yield of recombinant anti-
body fragments (data not shown). It was noteworthy that no 
host  cell  lysis  was  observed  during  IPTG  induction  of  the 
zipFv or zipFv-AP fusion proteins whereas over-expression of 
SP112 in the periplasm of E. coli caused host cell lysis (data 
not  shown).
    To  determine  the  antigen-binding  specificity  of  the  anti-
body fragments present in the cytoplasmic extracts of the host 
cells,  ELISA  was  performed  using  microtiter  plates  coated 
with recombinant PDC-E2, recombinant human IL-15, MBP or 
BSA. Anti-myc tag mAb was used for detecting the antibody 
fragments bound to antigens. As shown in Fig. 2, the zipFv- 
112 and its AP fusions, the zipFv-112(H-AP) and the zipFv- 
112(L-AP), specifically reacted to PDC-E2 only, but not to any 
other  negative  control  antigens,  demonstrating  that  the  re-
combinant antibody fragments of the zipFv and the zipFv-AP 
f o r m a t s  r e t a i n e d  t h e  a n t i g e n - b i n d i n g  s p e c i f i c i t y  o f  S P 1 1 2 ,  
even if they were produced in the cytoplasm of the host cells. 
This also implied that the proper disulfide bonds were formed 
between the VH-Fos-myc fragment and the VL-Jun-S1 fragment 
i n  t h e  c y t o p l a s m  o f  t h e  trx  gor m u t a n t  E.  coli.
    Since Fig. 2 showed that the zipFv-112 fragment exhibited 
the weakest antigen-binding signal among the three antibody 
fragments,  yield  of  the  functional  zipFv-112,  the  zipFv-112 
(H-AP)  and  the  zipFv-112(L-AP)  in  the  cytoplasmic  extracts 
were compared by ELISA (Fig. 3). The cytoplasmic extracts 
from the cells that grown at the exactly same experimental 
conditions were prepared and serial dilutions were made in 
MPBS. Mouse anti-myc tag mAb followed by goat anti-mouse 
IgG-HRPO  conjugated  was  used  to  detect  the  VH-Fos-myc 
fragments  of  the  zipFv-112  and  the  zipFv-112(L-AP)  or  the 
VH-Fos-myc-AP fragments of the zipFv-112(H-AP) that bound Cytoplasmic Expression of zipFv Fragments in E. coli
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Figure 2. ELISA to prove antigen-binding specificity of zipFv-112 and
its fusions with alkaline phosphatase produced in the cytoplasm of 
Origami(DE3) cells. Origami(DE3) cells transformed with pCzFv-112, 
pCzFvHAP-112 or pCzFvLAP-112 were grown in the presence of 0.1
mM IPTG, and the presence of PDC-E2-specific zipFv antibody 
fragments (zipFv-112, zipFv-112(H-AP) or zipFv-112(L-AP)) in the 
cytoplasmic extracts was determined by ELISA. Mouse anti-myc tag 
mAb was used for a primary antibody as described under Materials
and Methods. MBP, IL-15 and BSA were used as negative control 
antigens, and TMB substrate was used to visualize signals. Data 
represent the average of three experiments±standard deviation.
Figure 3. Comparison of antigen-binding reactivity of the zipFv-112 
and its fusions with alkaline phosphatase produced in the cytoplasm 
of Origami(DE3) cells by ELISA using anti-myc mAb for detecting the
VH-Fos-myc fragments. Origami(DE3) cells producing zipFv-112, zipFv-
112(H-AP) and zipFv-112(L-AP) were grown in the presence of 0.1 
mM IPTG, and the presence of PDC-E2-specific zipFv-AP antibody 
fragments in the serial dilutions of the cytoplasmic extracts was 
determined by ELISA using anti-myc mAb followed by goat anti-mouse
IgG-HRPO conjugated for detecting the VH-Fos-myc or the VH-Fos- 
myc-AP fusions as described under Materials and Methods. TMB 
substrate was used to visualize signals. Data represent the average of
three experiments±standard deviation.
Figure 4. Comparison of antigen-binding reactivity of anti-PDC-E2 
zipFv fused with alkaline phosphatase by ELISA. Origami(DE3) cells 
producing the zipFv-112(H-AP) and the zipFv-112(L-AP) were grown 
in the presence of 0.1 mM IPTG, and the presence of PDC-E2-specific
zipFv-AP antibody fragments in the serial dilutions of the cytoplasmic
extracts was determined by ELISA using AP substrate, pNPP, for 
detecting AP activity of the VH-Fos-myc-AP or the VL-Jun-AP fusions 
as described under Materials and Methods. MBP was used as a 
negative control antigen. Data represent the average of three ex-
periments±standard deviation.
to  PDC-E2.  The  results  revealed  that  the  zipFv-112(H-AP) 
showed about 4 times higher binding signal to PDC-E2 than 
that of the zipFv-112(L-AP) and 10 times higher than that of 
the zipFv-112, implying that the AP fusion at the C-terminus 
of the V H-Fos-myc of the zipFv increases yield of the func-
tional antibody fragments uppermost. To confirm this finding, 
e x p e r i m e n t s  w e r e  p e r f o r m e d  a s  s a m e  a s  F i g .  3  u s i n g  t h e  
same cytoplasmic extracts containing the zipFv-112(H-AP) or 
the zipFv-112(L-AP), except that AP substrate (pNPP) instead 
of anti-myc tag mAb was directly applied to visualize ELISA 
signals (Fig. 4). Unexpectedly, the data indicated that PDC- 
E2-binding  signal  of  the  zipFv-112(H-AP)  was  about  5-fold 
lower  than  that  of  the  zipFv-112(L-AP).  It  implies  that  that 
an AP domain of the VL-Jun-S1 would block the myc-tag epit-
ope of the VH-Fos-myc domain that recognized by anti-myc 
tag  mAb  in  the  zipFv-112(L-AP).
Western blot analysis to determine the expression 
level of the VH and the VL fusion molecules
To  understand  these  contradictory  results,  cell  lysates  of 
Origami(DE3) trxB gor cells housing pCzFv-112, pCzFvHAP- 
112 or pCzFvLAP-112 were prepared, and the same concen-
tration of total proteins were analyzed by western blot (Fig. 
5A). Mouse anti-myc tag mAb followed by anti-mouse IgG-AP 
c o n j u g a t e d  w a s  u s e d  t o  d e t e r m i n e  e x p r e s s i o n  l e v e l  o f  t h e  
VH-Fos-myc of the zipFv-112 or the zipFv-112(L-AP), and the Cytoplasmic Expression of zipFv Fragments in E. coli
Byung-ung Hur, et al.
41 IMMUNE NETWORK http://www.ksimm.or.kr Volume 10 Number 2 April 2010
Figure 5. Western blot showing the expression of the VH-Fos-myc, the
VH-Fos-myc-AP or the VL-Jun-AP fragments of the zipFv-112, the 
zipFv-112(H-AP) and the zipFv-112(L-AP). Origami(DE3) cells express-
ing the zipFv-112, the zipFv-112(H-AP) and the zipFv-112(L-AP) were 
grown in 2× YT/amp medium supplemented with 0.1 mM IPTG, and
total proteins in the cell lysates were separated by using 12% SDS- 
PAGE at reducing (A, lane 1 on B) and non-reducing (Lane 2 on B)
condition. Western blot was performed using either mouse anti-myc 
tag mAb followed by goat anti-mouse IgG-AP conjugated or NBT/BCIP
substrate directly as described under Materials and Methods to detect
the presence of the VH-Fos-myc and the VH-Fos-myc-AP, or AP activity
of the VH-Fos-myc-AP and the VL-Jun-AP polypeptides, respectively.
VH-Fos-myc-AP  fragment  of  the  zipFv-112(H-AP)  in  the  cell 
lysates. In addition, the AP activity of the VH-Fos-myc-AP of 
the  zipFv-112(H-AP)  and  the  VL-Jun-S1-AP  of  the  zipFv-112 
(L-AP)  was  also  measured  by  applying  NBT/BCIP  substrate 
directly to the blot. The denstometric analysis of the blot re-
vealed  that  the  VH-Fos-myc  (21  kDa)  of  the  zipFv-112  was 
expressed about 5-fold higher than the VH-Fos-myc-AP (67.5 
kDa)  of  the  zipFv-112(H-AP)  and  4-fold  higher  than  the 
VH-Fos-myc of the zipFv-112(L-AP), even though the zipFv- 
112 showed the weakest antigen-binding signal in ELISA as 
shown in Fig. 3. To resolve this contradiction we carried out 
w e s t e r n  b l o t  a n a l y s i s  o f  t h e  c e l l  l y s a t e  e x p r e s s i n g  t h e  
zipFv-112  at  reducing  and  non-reducing  conditions  of  12% 
SDS-PAGE using anti-myc mAb, and the results revealed that 
only 7% of total VH-Fos-myc fragments in the cytoplasm of 
Origami(DE3) cells formed the functional zipFv molecules ac-
cording  to  densitometry  analysis,  indicating  that  majority  of 
the VH-Fos-myc and the VL-Jun-S1 fragments were not prop-
erly dimerized each other in the cytoplasm of Origami(DE3) 
cells (Fig. 5B). On the other hand, the fusion of an AP moiety 
at the C-terminus of either the V H-Fos-myc or the VL-Jun-S1 
resulted  in  lower  expression  of  the  VH-Fos-myc  of  both 
zipFv-112(H-AP)  and  zipFv-112(L-AP).  Difference  in  ex-
pression  level  between  the  VH-Fos-myc-AP  of  the  zipFv- 
112(H-AP)  and  the  VH-Fos-myc  of  the  zipFv-112(L-AP)  was 
meager, although the zipFv-112(H-AP) showed a 4-fold high-
e r  b i n d i n g  s i g n a l  t o  P D C - E 2  t h a n  t h e  z i p F v - 1 1 2 ( L - A P )  a s  
shown  in  Fig.  3.
    Interestingly, blot data by using AP substrate (NBT/BCIP) 
directly showed that the VL-Jun-S1-AP of the zipFv-112(L-AP) 
seemed  to  be  produced  50-fold  higher  than  the  VH-Fos- 
myc-AP of the zipFv-112(H-AP) in the cytoplasm of the cells. 
This may explain a 5-fold higher antigen-binding signal of the 
zipFv-112(L-AP) than that of the zipFv-112(H-AP) as shown 
in Fig. 4. However, additional SDS-PAGE analysis followed 
by Coomassie blue staining revealed that the higher AP activ-
i t y  o f  t h e  V L-Jun-S1-AP  of  the  zipFv-112(L-AP)  didn’t  come 
from  the  higher  expression  level  of  the  fragment  than  the 
VH-Fos-myc-AP  of  the  zipFv-112(H-AP)  (data  not  shown). 
Taken together, the data imply that the positioning of the AP 
moiety at the C-terminus of the VH-Fos-myc somehow hinders 
AP activity. Unfortunately, we were not able to present west-
ern blot data showing VL-Jun-S1 and VL-Jun-S1-AP expression 
level  because  commercial  anti-S1  tag  mAb  produced  too 
much background on the blot. Our unpublished observation 
indicated  that  VH  domain  usually  has  a  higher  tendency  to 
aggregate each other compared to VL domain when it is ex-
pressed in E. coli probably due to the hydrophobic residues 
exposed outward. Therefore, we assume that presence of AP 
seemed to reduce this self-aggregation probably by conceal-
ing hydrophobic residues in the variable regions (33), result-
i n g  i n  t h e  i n c r e a s e  o f  f u n c t i o n a l  z i p F v - A P  m o l e c u l e s  c o m -
p a r e d  w i t h  a  z i p F v  f o r m a t .Cytoplasmic Expression of zipFv Fragments in E. coli
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Figure 6. Comparison of antigen-binding reactivity of the zipFv- 
112(L-AP) and the zipFv-112(H-AP) produced in the cytoplasm of 
Origami(DE3) cells by ELISA using anti-myc mAb for detecting signals.
Origami(DE3) cells producing zipFv-112(L-AP) and zipFv-112(H-AP) 
were grown in the presence of 0.1 mM IPTG, and presence of the 
functional zipFv-AP with PDC-E2 binding reactivity in the serial 
dilutions of the cytoplasmic extracts was determined by ELISA using 
mouse anti-myc mAb followed by goat anti-mouse IgG-HRPO con-
jugated for detecting the VH-Fos-myc or the VH-Fos-myc-AP fragments.
Data represent the average of three experiments±standard deviation.
Effect of an irrelevant fusion moiety at the C-terminus 
of the VH-Fos-myc on the functionality of the zipFv- 
112(L-AP) construct
W e  f ur th e r i nv e st ig at e d to  s ee  w h et h er  in c or po rat io n  o f a n 
irrelevant  protein,  such  as  DNA-binding  domain  of  AraC 
(AraCDNA), at the C-terminus of the VH-Fos-myc of the zipFv- 
112(L-AP)  might  improve  detection  of  the  antigen-binding 
zipFv-112(L-AP) by anti-myc tag mAb while keeping its high 
AP activity. AraCDNA was chosen because the gene fragment 
encoding the protein with appropriate restriction enzyme rec-
ognition sites was readily available in our laboratory, and it 
had been acknowledged that the domain could be produced 
in soluble form in the cytoplasm of E. coli (34). The gene 
fragment of the AraCDNA was cloned at the 3' end of myc tag 
of  the  pCzFvLAP-112  to  construct  the  pCzFvHADLAP  as 
shown in Fig. 1, and the resulting zipFv-112(H-AD/L-AP) frag-
m e n t s  w e r e  p r o d u c e d  i n  O r i g a m i ( D E 3 )  c e l l s .  T h e  a n t i g e n -  
binding  intensity  of  the  zipFv-112(L-AP)  and  the  zipFv-112 
(H-AP) was compared by ELISA using anti-myc tag mAb as 
Fig. 3 (Fig. 6). The ELISA results showed that the fusion of 
AraCDNA domain at the C-terminus of the VH-Fos-myc of the 
zipFv-112(L-AP)  restored  the  antigen-binding  signal  of  the 
zipFv-112(H-AD/L-AP)  to  the  same  degree  as  that  of  the 
zipFv-112(H-AP), indicating that the presence of a irrelevant 
protein moiety at the C-terminus of the VH-Fos-myc exposes 
myc  epitope  properly.  In  terms  of  AP  activity,  the  zipFv- 
112(H-AD/L-AP) showed the similar degree of antigen-bind-
ing intensity as the zipFv-112(L-AP) when AP substrate was 
u s e d  d i r e c t l y  i n  E L I S A  ( d a t a  n o t  s h o w n ) .
Effect of DsbC on the functional expression of the 
zipFv-AP fragments
Co-expression of chaperone proteins such as the Skp chaper-
one  protein  with  antibody  fragments  had  been  reported  to 
reduce toxicity and to enhance the proper folding of scFv or 
Fab fragments expressed in E. coli (35), and Levy et al dem-
onstrated that co-expression of Skp or DsbC chaperone pro-
tein increased the cytoplasmic production of functional Fab 
fragments  up  to  5-6-fold  (23).  Additionally,  DsbC  co-ex-
pression  increases  the  yield  of  tissue  plasminogen  activator 
(tPA) in the cytoplasm of E. coli by more than 20-fold (36). 
Since  only  minor  fraction  (＜10%)  of  total  VH-Fos-myc  di-
merized  with the  VL-Jun-S1 fragments  to  become  functional 
zipFv or zipFv-AP, we assumed that the same strategy may 
work  for  the  improved  expression  of  the  functional  zipFv 
fragments.
    To test whether co-expression of DsbC further improves a 
production  of  the  functional  zipFv-112(H-AD/L-AP),  DsbC 
gene  without  signal  peptide  was  cloned  into  pCDFDuet 
vector.  The  resulting  pCDF-DsbC  construct  was  electropo-
rated into Origami(DE3) cells, and the cytoplasmic expression 
o f  a  l e a d e r l e s s  v e r s i o n  o f  D s b C  ( 2 1 7  a m i n o  a c i d s ,  a p p r o x -
imately 24 kDa in size) upon IPTG induction was confirmed 
by 12% SDS-PAGE (data not shown). Electrocompetent Origa-
mi(DE3)  cells  housing  pCDF-DsbC  were  transformed  with 
p C z F v H A D L A P - 1 1 2 ,  a n d  E L I S A  w a s  p e r f o r m e d  t o  c o m p a r e  
PDC-E2-binding  intensity  of  the  zipFv-112(H-AD/L-AP)  ex-
pressed with or without DsbC (Fig. 7). The data revealed that 
the  zipFv-112(H-AD/L-AP)  with  DsbC  gave  about  1.5-fold 
higher  ELISA  signal  to  the  antigen  than  that  of  zipFv-112 
(H-AD/L-AP) without DsbC when anti-myc tag mAb was used 
for detecting signals (Fig. 7A). However, no beneficial effect 
was observed on the VL-Jun-S1-AP stabilization since no im-
provement  on  antigen-binding  signal  was  found  (Fig.  7B), 
suggesting that cytoplasmic co-expression of DsbC does not 
improve  functional  dimerization  of  the  VH-Fos-myc-AD  and 
the  VL-Jun-S1-AP  significantly.
    Considering that cytoplasmic Fab showed substantial anti-
gen-binding  reactivity  even  at  200-300-fold  dilution  (23,24), 
it appeared that the zipFv-AP fusions showed much weaker Cytoplasmic Expression of zipFv Fragments in E. coli
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Figure 7. Effect of DsbC on the production of functional zipFv-112(H-AD/L-AP) determined by ELISA. Origami(DE3) cells carrying pCDF-DsbC
were transformed with the pCzFvHADLAP-112, and grown in the presence of 0.1 mM IPTG. Presence of the functional zipFv-112(H-AD/L-AP) 
that bound to PDC-E2 with or without DsbC co-expression was determined using serial dilutions of the cytoplasmic extracts. (A) Mouse anti-myc
mAb followed by goat anti-mouse IgG-HRPO conjugated or (B). pNPP, AP substrate, was used to detect antigen-binding signals in ELISA. Data 
represent the average of three experiments±standard deviation.
antigen-binding intensity compared to the Fab fragments pro-
duced by cytoplasmic expression. We assume that this might 
come from the different experimental setups in that we pre-
pared 1.5 ml of the cytoplasmic extracts from 3 ml culture, 
but Venturi et al used 10 ml of the cytoplasmic extracts ob-
tained from 2 liters of culture for ELISA (24), meaning that 
their  Fab preparation  should give  an 100-fold higher signal 
than ours. In the case of the zipFv-112(H-AD/L-AP), it gave 
a good antigen-binding signal at 1/32 dilution factor, and it 
can be inferred from the results that this construct would pro-
duce as much as 10-fold higher yield of functional cytoplas-
mic antibody fragments than Fab format. It is possible that 
high expression rate of our zipFv-AP fusions compared to Fab 
fragments may come from the different IPTG induction proto-
col for recombinant antibody production that we used 27
oC 
16 h, whereas cytoplasmic Fab expression was performed at 
37
oC 4 h. Venturi et al also reported that 50∼250 times high-
er yield of Fab fragments could be obtained by cytoplasmic 
expression than in the periplasmic space, but we were not 
able to confirm this observation since we didn’t have peri-
plasmic  expression  module  for  the  zipFv  or  the  zipFv-AP 
fusions.
  I t  i s  p o s s i b l e  t h a t  f u n c t i o n a l  z i p F v  f r a g m e n t s  m i g h t  f o r m  
more efficiently than Fab fragments in the cytoplasm of the 
mutant E. coli because the zipFv requires four pairs of disul-
fides, two pairs of disulfides in the variable regions and an-
other  two  pairs  between  Fos  and  Jun  zipper,  whereas  Fab 
needs five pairs in total, including one intramolecular disul-
fide in the CH1, one in CL kappa, and an intermolecular disul-
fide linking. However, comparison of the yield between the 
zipFv and Fab above is only circumstantial unless an identical 
antibody gene is expressed using the same expression mod-
ule at the same experimental condition. Additionally, (His)6 
tag needs to be implemented to zipFv or zipFv-AP format for 
purification  of  the  molecules  to  address  the  issues  on  the 
yield of the antibody molecules precisely and quantitatively.
DISCUSSION
In this study, we demonstrated that a functional Fv fragment 
can  be  generated  by  dimerizing  VH a n d  V L  fragments  with 
a well-known Fos-Jun  zipper, and a resulting zipFv and its 
derivative  fused  with  AP  (zipFv-AP)  can  be  produced  as  a 
f u n c t i o n a l  f o r m  i n  t h e  c y t o p l a s m  o f  O r i g a m i ( D E 3 )  trxB  gor 
mutant E. coli strain. Interestingly, fusion of AP moiety to the 
zipFv-112 improved formation of the functional zipFv-AP mol-
ecules in the cytoplasm of host cells regardless of its location, 
and also influenced the conformation of the zipFv-AP mole-
cules  depending  on  its  location  as  shown  by  the  zipFv112 
(H-AP) and the zipFv-112(L-AP). Additionally, incorporation 
of  the  AraCDNA  domain  into  the  zipFv-112(L-AP)  [zipFv- 
112(H-AD/L-AP)]  improved  folding  of  the  zipFv-AP  mole-
cules.  In  contrast  to  previous  reports,  cytoplasmic  co-ex-
pression of DsbC seemed not as quite beneficial as expected. Cytoplasmic Expression of zipFv Fragments in E. coli
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Currently,  we  are  exploring  the  possibility  of  replacing  the 
AraCDNA  domain  of  the  zipFv-112(H-AD/L-AP)  with  other 
functional  proteins,  for  example  green  fluorescent  protein 
(GFP), to make tri-functional antibody fragments. Considering 
that the production of recombinant antibody fragments fused 
with functional molecules such as AP is important in the de-
velopment of molecular diagnostic reagents for biomedical re-
search, we believe that our zipFv-AP constructs may provide 
an alternative antibody format for producing bi-functional an-
tibody fragments in the cytoplasm of E. coli in a secure and 
convenient manner, and possibly for the development of di-
verse  antibody  contents  for  proteome  analysis.
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